S. Molica

908 total citations
26 papers, 545 citations indexed

About

S. Molica is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, S. Molica has authored 26 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Hematology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in S. Molica's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Multiple Myeloma Research and Treatments (5 papers). S. Molica is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Multiple Myeloma Research and Treatments (5 papers). S. Molica collaborates with scholars based in Italy and United Kingdom. S. Molica's co-authors include Domenico Levato, Piero Galieni, Luciano Guardigni, Maurizio Martelli, Patrizia Gentilini, Patrizia Albertini, S Tura, Francesco Zaja, Francesco Di Raimondo and Maurizio Bendandi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

S. Molica

25 papers receiving 531 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Molica Italy 11 286 196 187 143 125 26 545
Hirotaka Takasaki Japan 16 317 1.1× 244 1.2× 148 0.8× 153 1.1× 80 0.6× 59 732
Christina Kalpadakis Greece 17 413 1.4× 235 1.2× 311 1.7× 177 1.2× 156 1.2× 48 727
J.P. Vannier France 10 264 0.9× 185 0.9× 109 0.6× 76 0.5× 203 1.6× 26 659
T.E. Witzig United States 9 388 1.4× 416 2.1× 162 0.9× 262 1.8× 200 1.6× 18 778
Almudena Santón Spain 17 475 1.7× 356 1.8× 158 0.8× 72 0.5× 171 1.4× 43 861
Paul‐André Bryon France 14 509 1.8× 338 1.7× 265 1.4× 85 0.6× 81 0.6× 18 687
A. M. Gianni Italy 15 201 0.7× 294 1.5× 83 0.4× 160 1.1× 109 0.9× 26 619
Tariq Muzzafar United States 14 220 0.8× 152 0.8× 176 0.9× 149 1.0× 95 0.8× 34 507
Vittorio Silingardi Italy 12 202 0.7× 342 1.7× 137 0.7× 80 0.6× 115 0.9× 28 619
Joan H. Admirand United States 17 413 1.4× 270 1.4× 294 1.6× 169 1.2× 134 1.1× 23 749

Countries citing papers authored by S. Molica

Since Specialization
Citations

This map shows the geographic impact of S. Molica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Molica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Molica more than expected).

Fields of papers citing papers by S. Molica

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Molica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Molica. The network helps show where S. Molica may publish in the future.

Co-authorship network of co-authors of S. Molica

This figure shows the co-authorship network connecting the top 25 collaborators of S. Molica. A scholar is included among the top collaborators of S. Molica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Molica. S. Molica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Picardi, Biagio, Stefano Rossi, Francesco Cortese, et al.. (2025). Management of Chyloperitoneum in Laparoscopic Colorectal Surgery for Cancer: A Case Report. Case Reports in Gastrointestinal Medicine. 2025(1). 6690258–6690258.
2.
Molica, S., David Allsup, & Diana Giannarelli. (2024). Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis. Blood. 144(Supplement 1). 4630–4630. 1 indexed citations
3.
4.
Piro, Eugenio, Maria Lentini, Luciano Levato, Antonio Russo, & S. Molica. (2018). Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox. Chemotherapy. 63(2). 107–110. 3 indexed citations
5.
Molica, S.. (2015). Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology. Expert Review of Hematology. 8(3). 277–281. 1 indexed citations
6.
Piro, Eugenio & S. Molica. (2011). A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence?. Acta Haematologica. 126(3). 163–168. 12 indexed citations
7.
Cicero, Giuseppe, et al.. (2010). 32 PAIN MANAGEMENT AND QUALITY LIFE IN BONE METASTASIS FROM BREAST CANCER: ROLE OF RADIOTHERAPY. Cancer Treatment Reviews. 36. S104–S104. 1 indexed citations
8.
Giuliani, Francesco, Evaristo Maiello, S. Molica, et al.. (2004). Irinotecan (CPT-11) and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Journal of Clinical Oncology. 22(14_suppl). 4235–4235. 1 indexed citations
9.
Morabito, Fortunato, Massimo Martino, Caterina Stelitano, et al.. (2002). Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma.. PubMed. 87(11). 1192–9. 34 indexed citations
10.
Raimondo, Francesco Di, Giuseppe A. Palumbo, S. Molica, & Rosario Giustolisi. (2001). Angiogenesis in Chronic Myeloproliferative Diseases. Acta Haematologica. 106(4). 177–183. 54 indexed citations
11.
Molica, S., Gaetano Vitelli, Domenico Levato, Diana Giannarelli, & G.M. Gandolfo. (2001). Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer. 92(4). 713–719. 30 indexed citations
12.
Broglia, Chiara, Raffaella Bertè, S. Molica, et al.. (2000). Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.. PubMed. 85(7). 722–8. 3 indexed citations
13.
Zinzani, Pier Luigi, Massimo Magagnoli, Piero Galieni, et al.. (1999). Nongastrointestinal Low-Grade Mucosa-Associated Lymphoid Tissue Lymphoma: Analysis of 75 Patients. Journal of Clinical Oncology. 17(4). 1254–1254. 223 indexed citations
14.
Rossi, Giulio, Paola Marroni, M. Paganuzzi, et al.. (1997). Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 11(1). 134–141. 44 indexed citations
15.
Molica, S., et al.. (1996). Intercellular adhesion molecules (ICAMs) 2 and 3 are frequently expressed in B cell chronic lymphocytic leukemia.. PubMed. 10(5). 907–8. 20 indexed citations
16.
Consarino, Caterina, et al.. (1995). Spectrum of β‐thalassemia mutations in Calabria: Implications for prenatal diagnosis. American Journal of Hematology. 48(2). 128–129. 3 indexed citations
17.
Molica, S., Domenico Levato, & Luciano Levato. (1993). Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up.. PubMed. 78(6). 374–7. 37 indexed citations
18.
Molica, S., et al.. (1990). Chronic myelomonocytic leukemia: A test of a proposed staging system. American Journal of Hematology. 35(2). 129–130. 5 indexed citations
19.
Molica, S. & A. Albertí. (1990). Recombinant alpha-2a interferon in treatment of B-chronic lymphocytic leukemia. A preliminary report with emphasis on previously untreated patients in early stage of disease.. PubMed. 75(1). 75–8. 20 indexed citations
20.
Catalano, Lucio, Ignazio Majolino, Pellegrino Musto, et al.. (1990). Alpha interferon in the treatment of chronic myelomonocytic leukemia.. PubMed. 74(6). 577–81. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hirotaka Takasaki Breakdown of academic impact, for papers by Christina Kalpadakis Breakdown of academic impact, for papers by J.P. Vannier Breakdown of academic impact, for papers by T.E. Witzig Breakdown of academic impact, for papers by Almudena Santón Breakdown of academic impact, for papers by Paul‐André Bryon Breakdown of academic impact, for papers by A. M. Gianni Breakdown of academic impact, for papers by Tariq Muzzafar Breakdown of academic impact, for papers by Vittorio Silingardi Breakdown of academic impact, for papers by Joan H. Admirand
Rankless by CCL
2026